Nurix Therapeutics, Inc. (NRIX)

NASDAQ: NRIX · Real-Time Price · USD
9.72
-0.04 (-0.41%)
At close: Oct 13, 2025, 4:00 PM EDT
9.90
+0.18 (1.85%)
After-hours: Oct 13, 2025, 7:50 PM EDT
-0.41%
Market Cap747.31M
Revenue (ttm)83.69M
Net Income (ttm)-244.79M
Shares Out 76.88M
EPS (ttm)-2.97
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,566,225
Open9.84
Previous Close9.76
Day's Range9.00 - 9.91
52-Week Range8.18 - 29.56
Beta2.34
AnalystsStrong Buy
Price Target28.29 (+191.05%)
Earnings DateOct 9, 2025

About NRIX

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton’s tyrosine kinase (BTK) degrader, that is in Phase 1A clinical trials f... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 286
Stock Exchange NASDAQ
Ticker Symbol NRIX
Full Company Profile

Financial Performance

In 2024, Nurix Therapeutics's revenue was $54.55 million, a decrease of -29.15% compared to the previous year's $76.99 million. Losses were -$193.57 million, 34.5% more than in 2023.

Financial Statements

Analyst Summary

According to 14 analysts, the average rating for NRIX stock is "Strong Buy." The 12-month stock price target is $28.29, which is an increase of 191.05% from the latest price.

Price Target
$28.29
(191.05% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Nurix: Bexobrutideg Advancement Presses Forward With H2 2025 Milestones

Nurix Therapeutics maintains a Strong Buy rating, driven by promising progress with its oral BTK degrader bexobrutideg for relapsed/refractory CLL. NRIX plans to initiate a pivotal single-arm phase 2 ...

2 days ago - Seeking Alpha

Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025

4 days ago - GlobeNewsWire

Nurix Therapeutics Presents Preclinical Data from Novel IRAK4 Degrader, GS-6791, Demonstrating Potent Inhibition of IL-1 and IL-36 in Vitro and Efficacy in a Model of Dermatitis

Presentation of preclinical data from novel IRAK4 protein degrader, GS-6791, discovered in Nurix's ongoing research collaboration with Gilead Sciences

26 days ago - GlobeNewsWire

Nurix Therapeutics, Inc. (NRIX) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Wells Fargo 20th Annual Healthcare Conference 2025 September 3, 2025 1:30 PM EDT Company Participants Arthur Sands - CEO, President & Director Conference Call P...

4 weeks ago - Seeking Alpha

Nurix Therapeutics, Inc. (NRIX) Presents At Baird Global Healthcare Conference 2025 (Transcript)

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Baird Global Healthcare Conference 2025 September 9, 2025 10:50 AM EDT Company Participants Arthur Sands - CEO, President & Director Conference Call Participant...

4 weeks ago - Seeking Alpha

Nurix Therapeutics, Inc. (NRIX) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Nurix Therapeutics, Inc. (NASDAQ:NRIX) H.C. Wainwright 27th Annual Global Investment Conference September 8, 2025 1:30 PM EDT Company Participants Arthur Sands - CEO, President & Director Conference ...

4 weeks ago - Seeking Alpha

Nurix Therapeutics, Inc. (NRIX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Nurix Therapeutics, Inc. (NASDAQ:NRIX) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 7:00 AM EDT Company Participants Arthur Sands - CEO, President & Director Conference ...

4 weeks ago - Seeking Alpha

Nurix Therapeutics to Participate in Upcoming Investor Conferences

SAN FRANCISCO, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targ...

6 weeks ago - GlobeNewsWire

Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors

NRIX's Bexobrutideg shows impressive ORR for refractory CLL/WM. I believe this positions it as a potential best-in-class BTK degrader in a sizable TAM. Nurix Therapeutics also works with other big pha...

3 months ago - Seeking Alpha

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Presented updated data for bexobrutideg (NX-5948) at EHA2025 and ICML-18, demonstrating a favorable safety profile and deepening responses in patients with r/r chronic lymphocytic leukemia (CLL) and W...

3 months ago - GlobeNewsWire

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targ...

3 months ago - GlobeNewsWire

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targ...

4 months ago - GlobeNewsWire

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targ...

4 months ago - GlobeNewsWire

Sanofi Exercises License Extension Option to Nurix's STAT6 Program

STAT6 is a key transcription factor within the IL4/IL13 signaling pathways which act as drivers of inflammation in allergic conditions Nurix to receive a $15 million license extension fee from Sanofi ...

4 months ago - GlobeNewsWire

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

SAN FRANCISCO, May 28, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targe...

4 months ago - GlobeNewsWire

Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

SAN FRANCISCO, May 15, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targe...

5 months ago - GlobeNewsWire

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

SAN FRANCISCO, May 14, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targe...

5 months ago - GlobeNewsWire

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Nurix's DEL-AI platform uses a first-in-class DEL Foundation Model trained on the  Company's proprietary DNA encoded library data

6 months ago - GlobeNewsWire

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Nurix's lead BTK degrader, bexobrutideg, demonstrates exceptional efficiency, with a single molecule degrading approximately 10,000 copies of BTK per hour

6 months ago - GlobeNewsWire

Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential

FDA IND clearance given for BTK degrader GS-6791, targeting inflammatory disorders, allowing Nurix Therapeutics, Inc. to receive a $5 million milestone payment from Gilead Sciences. Nurix has earned $...

6 months ago - Seeking Alpha

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Collaboration partner, Gilead Sciences, to begin Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) study in healthy volunteers in Q2 2025 GS-6791/NX-0479 has potential clinical app...

6 months ago - GlobeNewsWire

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

NX-5948 assigned the nonproprietary name “bexobrutideg” U.S. FDA Orphan Drug Designation granted to bexobrutideg for the treatment of Waldenström macroglobulinemia Achieved $7M in milestones and a $15...

6 months ago - GlobeNewsWire

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

The undisclosed target is a central regulator of inflammation that is distinct from the previously disclosed STAT6 program Nurix DEL-AI drug discovery engine generated a drug discovery program to this...

6 months ago - GlobeNewsWire

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

SAN FRANCISCO, March 25, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of tar...

7 months ago - GlobeNewsWire